URGN Q2 2019 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18,000-95.1% YoY

Gross Profit

$18,000100.0% margin

Operating Income

-$24M-131961.1% margin

Net Income

-$22M-124872.2% margin

EPS (Diluted)

$-1.08

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$239M

Total Liabilities

$14M

Stockholders' Equity

$225M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18,000	$364,000	-95.1%
Gross Profit	$18,000	$46,000	-60.9%
Operating Income	-$24M	-$18M	-28.9%
Net Income	-$22M	-$18M	-24.7%